Throughout all the major cannabis news that has been making headlines in Europe, the U.S., and across the globe over the past ten or so years, France has been almost nowhere in the mix.
A parliamentary committee wants to change that as soon as possible and the members are urging the government to initiate a medical cannabis experiment and figure out the best way to address medical cannabis concerns.
An Urgent Call To Action
The committee made this demand in a document, asking for a budget that would support some kind of experiment surrounding medical cannabis and its potential for legalization.
“It’s very important that funding for the medical cannabis experiment is now integrated into this process,” said Benjamin-Alexandre Jeanroy, CEO of Augur Associates in Paris, back in 2019 regarding the importance of moving forward and making something happen. While France has technically approved such an experiment a year ago through legal channels, there needs to be actual implementation to get something off the ground and into the trial stage so that progress can be monitored.
Robin Reda of the French National Assembly and president of the committee claims that she believes France “has fallen alarmingly behind its European neighbors” in terms of cannabis reform overall. “The bulk of the technical work was done before the health crisis,” Reda added, explaining that she doesn’t believe this delay is due to COVID alone, as there has been plenty of time. She instead blames “bureaucratic blockage” and wonders why the government is not moving forward.
Under the new, experimental program, if it is allowed to get started, as many as 3,000 people could be enrolled to try medical cannabis as treatment. At first, the program would probably be dependent on North American cannabis grows until the government can set up its own grow structure for patients. Advocates would like to see this program get started as early as 2021.
In addition to those on the committee supporting cannabis, 50 doctors, scientists, and patients expressed these same concerns earlier this month in an op-ed published in Le Parisien. They argued that because of the lengthy delay on medical cannabis programs, there is no access for patients, causing those who need medical cannabis to look outside legal channels and turn to the black market. They also argue that the framework has already been laid.
“Two years ago, this officially began within the National Agency for the Safety of Medicines and Health Products (ANSM) at the request of the previous Minister of Health, Agnès Buzyn,” they stated (originally in French) in their op-ed. “Since September 2018, work has then been initiated within a multidisciplinary, scientific committee of the ANSM. They assessed the scientific relevance of providing access to cannabis-based, pharmaceutical standard products for chronically ill patients with little or no relief from their suffering by their treatments.”
While this would only be a small step towards legal cannabis in France, it would definitely be the biggest step that has been taken since a medical cannabis experiment was approved. If this experiment goes forward, it truly could be the start of both medical and recreational cannabis in the European country.